^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XmAb968

    i
    Associations
    News

    Trials

    Company:
    Xencor
    Drug class:
    CD3 agonist, CD38 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia (PRO00041908) (NCT05038644)
    Phase 1
    Ehab L Atallah
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    02/02/2022
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    CD38
    |
    CD38 expression
    |
    XmAb968